Marker Therapeutics, Inc.

Tagged: triple negative breast cancer

TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.

Read More

TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.

Read More

TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer

TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).

Read More

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.

Read More

TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials

TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.

Read More

TapImmune Doses First Patient in its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

…Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016

JACKSONVILLE, FL, June 21, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced reaching a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200.

Read More

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

…Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization

JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ –

TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.

Read More